PSI Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

PSI Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-190	Closed	-$6.22K	–	617
2025 Q1	$6.22K	Hold	190	–	–	﹤0.01%	512
2024 Q4	$6.87K	Hold	190	–	–	﹤0.01%	581
2024 Q3	$5.92K	Hold	190	–	–	﹤0.01%	634
2024 Q2	$5.08K	Hold	190	–	–	﹤0.01%	639
2024 Q1	$6.48K	Hold	190	–	–	﹤0.01%	552
2023 Q4	$5.5K	Hold	190	–	–	﹤0.01%	609
2023 Q3	$5.24K	Hold	190	–	–	﹤0.01%	585
2023 Q2	$5.71K	Hold	190	–	–	﹤0.01%	571
2023 Q1	$6.88K	Hold	190	–	–	﹤0.01%	496
2022 Q4	$6.78K	Hold	190	–	–	﹤0.01%	479
2022 Q3	$6K	Hold	190	–	–	﹤0.01%	507
2022 Q2	$5K	Hold	190	–	–	﹤0.01%	578
2022 Q1	$6K	Hold	190	–	–	﹤0.01%	541
2021 Q4	$6K	Hold	190	–	–	﹤0.01%	575
2021 Q3	$5K	Buy	+190	New	+$5.1K	﹤0.01%	584
2020 Q1	–	Sell	-190	Closed	-$4K	–	524
2019 Q4	$4K	Buy	+190	New	+$4.61K	﹤0.01%	580

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

PSI Advisors's SUPN Position: Q2 2025 in Review

PSI Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 190 shares — an estimated $6.22K sold.

PSI Advisors first reported a position in SUPN in Q4 2019 and held it in 16 quarters. The position peaked at $6.88K in Q1 2023. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

PSI Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
PSI Advisors sold 190 Supernus Pharmaceuticals shares in Q2 2025, an estimated $6.22K.
PSI Advisors first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 16 quarters.
PSI Advisors's Supernus Pharmaceuticals position peaked at $6.88K in Q1 2023.
295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.